Holen Sie sich die Stockscreener-App
109.95
0.07%
-0.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$110.03
Offen:
$110.73
24-Stunden-Volumen:
8.02M
Relative Volume:
1.22
Marktkapitalisierung:
$137.00B
Einnahmen:
$28.75B
Nettoeinkommen (Verlust:
$480.00M
KGV:
297.16
EPS:
0.37
Netto-Cashflow:
$10.83B
1W Leistung:
+5.64%
1M Leistung:
+18.28%
6M Leistung:
+46.35%
1J Leistung:
+50.20%
1-Tages-Spanne:
$109.77
$111.03
1-Wochen-Bereich:
$104.00
$111.03
52-Wochen-Spanne:
$62.07
$111.03
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
109.95 | 137.00B | 28.75B | 480.00M | 10.83B | 0.37 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise - Inkl
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP - Clinical Trials Arena
Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings - Yahoo Finance
EU okays Gilead's seladelpar for primary biliary cholangitis - FirstWord Pharma
Advyzon Investment Management LLC Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Handelsbanken Fonder AB Buys 51,453 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Good Life Advisors LLC - MarketBeat
Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup - Quartz
Gilead Sciences: Buy Rating Backed by Strong Q4 Performance, Strategic Initiatives, and Promising Pipeline - TipRanks
Kornitzer Capital Management Inc. KS Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis - Marketscreener.com
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis - BioSpace
Kentucky Retirement Systems Insurance Trust Fund Purchases 17,439 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Valley Wealth Managers Inc. - MarketBeat
Gilead Sciences acquires $14.9 million in Arcus Biosciences stock - Investing.com
Gilead Sciences acquires $14.9 million in Arcus Biosciences stock By Investing.com - Investing.com Australia
Gilead Sciences Gets Conditional Marketing Authorization for Liver Disease Treatment in European Economic Area - Marketscreener.com
Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells 2,500 Shares of Stock - MarketBeat
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease - CSRwire.com
Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up - Insider Monkey
Assembly Biosciences and Gilead's genital herpes treatment gives positive results in early stage trial - Seeking Alpha
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Gilead deal staves off generic HIV drugs for another six years - Life Sciences Intellectual Property Review
Alberta Investment Management Corp Sells 151,193 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Werba Rubin Papier Wealth Management Sells 6,179 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead, Janssen Settle HIV Treatment Suits With Lupin, Apotex - Law360
CapWealth Advisors LLC Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
AustralianSuper Pty Ltd Has $105.14 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
How Is The Market Feeling About Gilead Sciences? - Benzinga
Deutsche Bank Upgrades Gilead Sciences (BIT:1GILD) - Nasdaq
Gilead Sciences stock hits 52-week high of $106.78 - Investing.com
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data - BioSpace
Deutsche Bank Aktiengesellschaft Upgrades Gilead Sciences (NASDAQ:GILD) to "Buy" - MarketBeat
Mcdonald Partners LLC Decreases Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
FDA sets June date for Gilead's twice-yearly HIV PrEP - pharmaphorum
Gilead Sciences, Inc. (NASDAQ:GILD) Position Lifted by Convergence Investment Partners LLC - MarketBeat
Truist Financial Corp Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Callahan Advisors LLC Has $604,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
New York State Common Retirement Fund Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Blue Trust Inc. Has $326,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Principal Financial Group Inc. Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Principal Securities Inc. Purchases 4,468 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Strategic Financial Concepts LLC Makes New $6.64 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead new drug applications for twice-yearly Lenacapavir for HIV Prevention accepted by USFDA under... - Medical Dialogues
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use - Pharmaceutical Technology
Arcus’s Casdatifan Differentiates, But Data Overshadowed By Gilead Opting Out - News & Insights
Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Update - MarketBeat
FDA Approves NDA for Gilead's new HIV Prevention Shot - Managed Healthcare Executive
Deutsche Bank Upgrades Gilead Sciences (WBAG:GILD) - Nasdaq
Deutsche Bank Upgrades Gilead Sciences (GILD) - Nasdaq
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Feb 18 '25 |
Sale |
104.09 |
2,500 |
260,225 |
169,061 |
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):